Navigation Links
Optimizing Büchi® Rotary Evaporator Applications

Introduction

Selecting the correct operating parameters for Büchi Rotary Evaporators is an important part of your application. Many variables must be considered, i.e. choosing the appropriate bath temperature, vacuum pressure, rate of evaporation, and accessory chiller—so it's no surprise to find more vapors collecting in the lab environment than in the receiving flask!

The following discussion offers a complete guide for optimizing your Büchi Rotary Evaporator application.

Choosing the bath and condenser temperature (20-40-60 Rule) The first topic of discussion is the 20-40-60 Rule. The recommended water bath temperature is 60°C. This minimizes evaporation from the bath, reduces the risk of burns, and minimizes the loss of heat energy into the lab environment. The bath temperature should be 20°C higher than the vapor pressure temperature of the solvent. In this example, a vacuum pressure is chosen to produce a vapor pressure temperature of 40°C.

(Calculating vacuum pressure will be discussed in the next section.) The condenser temperature should be 20°C lower than the vapor pressure temperature of the solvent. In this example, the vapor pressure temperature is 40°C so the condenser temperature should be 20°C.

To conserve water and maintain lower condenser temperatures, Lauda® Chillers may be used as an alternative cooling method over standard tap water methods. (Choosing an appropriate Chiller will be discussed in later sections.)

The above example illustrates the 20-40-60 Rule
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8

Related biology technology :

1. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. Optimizing electroporation parameters
4. Optimizing electroporation parameters
5. Optimizing Büchi® Rotary Evaporator Applications
6. Optimizing Bchi Rotary Evaporator Applications
7. Optimizing electroporation parameters
8. Optimizing electroporation parameters
9. Optimizing electroporation parameters
10. Optimizing electroporation parameters
11. Optimizing electroporation parameters
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Optimizing uuml chi reg Rotary Evaporator Applications

(Date:5/16/2008)..., May 16 /- Highlighting th... its current product,pipeline, Michael V. Novinski.... (Nasdaq: EMIS ), was featured in an extensive i...nscript (TWST). Established more than 40,years ago..., including,CEOs, analysts and money managers, and...
(Date:5/16/2008)...if., May 16 /- MAP,Pharmace...t the Company will,present at the 2008 Citi Invest...esday, May 21, 2008, at 9:00 am (ET) in New York C...available on the Investor,Relations section of MAP....com . A replay will also be available within 24 h...
(Date:5/15/2008)...ERYVILLE, Calif., May 16 /-...harmaceuticals, Inc.,(Nasdaq: ONXX ) today announ...erican Society of Clinical Oncology (ASCO) annual ... (sorafenib) tablets in multiple tumor types as,a ... "Data at ASCO will expand upon and support the p...
(Date:5/15/2008)...ructures that scatter and channel light, Universit...e working toward thin-film single junction solar c...ight-to-electricity conversion efficiencies. This ... of 31 percent efficiency for conventional single ...st from the U.S. Department of Energys Solar Ameri...
Breaking Biology Technology:Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript 2Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript 3Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 6Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 7UC San Diego nanostructures will raise thin-film solar cell efficiency 2
...ufacturer,s product going straight to the lap of t...er, a roofer or a big business, a single-item purc...e inventories. No middle layers, no costly structu...e or any unnecessary tapes. The supply chain is fa...one quick delivery. , ,It,s like getting a pizza d...
...t progress in improving business conditions in the... restrictions if the state is to better capitalize...ee heard on Tuesday. , ,"Today it is easier to leg...nvest in emerging, growth Wisconsin companies," sa...o formerly worked for the Wisconsin Department of ...
...s a fossil cat or dog in Precambrian rock is the d... But that hasn,t happened. In fact, the Earth,s fo...rough the ages: Today,s living species descended -...lived in our ancient past. , ,Creationists don,t b...handiwork in its most literal sense, complete with...
...ega announced on Tuesday a settlement of a contrac...en pending before the U.S. District Court in Delaw... will hold a worldwide non-exclusive license from ...round Benitec,s DNA-directed RNA interference (ddR...ned payment of cash and continued royalties from c...
Other Biology Technology:Move over B2B, B2C -- it's M2E time 2Move over B2B, B2C -- it's M2E time 3Regulations still stymie business investment in high-growth companies 2Regulations still stymie business investment in high-growth companies 3Regulations still stymie business investment in high-growth companies 4Debate over `intelligent design' is a not-so-wise diversion from science education 2Debate over `intelligent design' is a not-so-wise diversion from science education 3
(Date:5/15/2008)...n Biometrics Business in First Quarter, WALL, N.J...ational,Inc. (OTC Bulletin Board: BKYI), a leader...ric identification solutions, today announced its,...h 31, 2008., 2008 First Quarter Consolidated Resu... the three months ended,March 31, 2008 was $2.5 mi...
(Date:5/15/2008)... Contrary to long-held assumptions, high-salt diet... investigators from the Albert Einstein College of...r conclusion after examining dietary intake among ...e U.S. The Einstein researchers actually observed ...ovascular disease (CVD) associated with lower sodi...
(Date:5/15/2008)...8) Argonne National Laboratory has signed a memor...ational Laboratory (SRNL) to collaborate on nuclea...jects in support of critical U.S. Energy Departmen...ies. , "The MOU allows Argonne to remain a leade...bert Rosner said. "Argonne has the nation,s larges...
(Date:5/15/2008)...nowledge that tuna aggregate under floating object... even large marine mammals. There is still no full...he past 20 years have seen purse-seine fishery ope...ions of fish. Fishermen cast off floating rafts eq...urse-seine net, deployed in a wide arc on either s...
Breaking Biology News(10 mins):BIO-key(R) Reports First Quarter 2008 Results 2BIO-key(R) Reports First Quarter 2008 Results 3New study casts further doubt on risk of death from higher salt intake 2Argonne-SRNL agreement supports critical DOE, national priorities 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 3Melanomas on Scalp and Neck More Deadly 17342 1Melanomas on Scalp and Neck More Deadly 17342 2HHS Extends Comment Period on Proposed MUP HPSA Rule 17339 1HHS Extends Comment Period on Proposed MUP HPSA Rule 17339 2Dr Elizabeth Brown Joins Argenta TEC 4741 1Dr Elizabeth Brown Joins Argenta TEC 4741 2NCRA Urges U S Reps Danny Davis and Judy Biggert to Approve in Conference the Higher Education Reauthorization Bill Providing Closed Captioning for 17335 1NCRA Urges U S Reps Danny Davis and Judy Biggert to Approve in Conference the Higher Education Reauthorization Bill Providing Closed Captioning for 17335 2
... be effective against not only multi drug-resistan... compound to treat the latent stage of infection a... the 2006 ASM Biodefense Research Meeting. , "The...ry different mechanism of action from any other dr...identified no cross resistance with existing drugs...
... an increased risk of the most common type of brai...ship between mobile phone use and risk of glioma. ... , The four year study by the Universities of Leed...Cancer Research, London found those who had regula...all risk of developing this type of tumour. , The...
...bones, big mysteries. So it,s a delicious irony th...rom small ?very small ?remains. , "Molecules are ...ogist Peggy Ostrom. "We,ve shown that proteins sur... about diseases, about where prehistoric animals f...re related to." , Ostrom joins six other scientis...
...thical concerns that hamper embryonic stem cell re...challenges. Chief among these is the doggedness wi...e tissue the moment they,re isolated from the body...to multiply them in the laboratory. And because ad...t to use them for treating disease. , Now, resear...
Other Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Mobile phone use not linked to increased risk of glioma brain tumours 2Next good dinosaur news likely to come from small packages 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3
96 Well Base Plate
... RNase Inhibitor is a recombinant human protein pr...tral pancreatic RNase A type enzymes. The mode of...ly binds RNases in a 1:1 ratio. The enzyme has bee...es and cell types. Addition of the ribonuclease in...
... (Chemical Inkjet Printer) is a revolutionary new ...n Macroarray Analysis, developed in conjunction wi...e strategy compliments established protocols in re...soelectric point and apparent molecular weight). H...
RNase Inhibitor (Ribonuclease inhibitor) is a 50 kDa recombinant enzyme used to inhibit RNase activity. It does not contain DNase or endonuclease activity. , Inhibits RNase activity, preventing degr
Biology Products: